SCHEMBL901475

SCHEMBL901475

CCOC(=O)CCc1cccc(F)c1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP4F2 P78329 2/20 0.55
CYP4A11 Q02928 2/20 0.55
NPC1 O15118 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
LMNA P02545 1/20 0.48
GLA P06280 1/20 0.48
AKR1C3 P42330 3/20 0.47
MAOB P27338 1/20 0.47
AKR1C2 P52895 1/20 0.47
TAAR1 Q96RJ0 3/20 0.46
MAPT P10636 1/20 0.46
PPARG P37231 1/20 0.46
PPARA Q07869 1/20 0.46
SYK P43405 1/20 0.46
ALOX5 P09917 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL642197 0.91 ALOX5 (0.54) CYP4F2CYP4A11NPC1LMNAGLA
SCHEMBL1205512 0.90 CYP4F2 (0.52) CYP4F2CYP4A11NPC1LMNAGLA
SCHEMBL9278298 0.89 PPARA (0.49) CYP4F2CYP4A11NPC1MAOBPPARG
SCHEMBL4425984 0.89 CYP4F2 (0.64) CYP4F2CYP4A11TDP1PPARGPPARA
SCHEMBL11066194 0.88 NPC1 (0.46) CYP4F2CYP4A11NPC1LMNAGLA
SCHEMBL879289 0.84 CYP4F2 (0.58) CYP4F2CYP4A11TDP1TAAR1PPARG
SCHEMBL2485584 0.84 MAOB (0.58) NPC1LMNAGLAMAOBMAPT
SCHEMBL901672 0.84 TAAR1 (0.53) AKR1C3MAOBAKR1C2TAAR1MAPT
SCHEMBL13104077 0.84 CYP4F2 (0.58) CYP4F2CYP4A11TDP1MAPTPPARG
SCHEMBL7857817 0.83 CYP4F2 (0.57) CYP4F2CYP4A11TDP1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021133915-A1 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute (US) 2021-07-01 WO disclosed
CN-107698528-A A kind of preparation method of 3-triazole compounds 湖南华腾制药有限公司 2018-02-16 CN disclosed
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LIMITED (GB) 2013-09-26 US disclosed
CN-103328479-A 7-hydroxy-pyrazolo [1,5-a ] pyrimidine compounds and their use as CCR2 receptor antagonists PROXIMAGEN LTD 2013-09-25 CN disclosed
EP-2621928-A1 7-HYDROXY-PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS Proximagen Limited (GB) 2013-08-07 EP disclosed
WO-2012041817-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS PROXIMAGEN LTD (GB) 2012-04-05 WO disclosed
CN-1159287-C Anticonvulsant and sentral nervous system-active bis (fluorophenyl) alkylamides NPSҩ�����޹�˾ 2004-07-28 CN disclosed
CN-1284056-A Anticonvulsant and sentral nervous system-active bis (fluorophenyl) alkylamides NPS PHARMA INC (US) 2001-02-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252951-A1 7-HYDROXY-PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND THEIR USE AS CCR2 RECEPTOR ANTAGONISTS CCR2, CCR5, CCR1 CYP4F2 1184/4885CYP4A11 639/4885NPC1 1464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.